A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
| 适应症 | Non-Small Cell Lung Cancer |
|---|---|
| 分期 | 2期 |
| 申办方 | AstraZeneca |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 30 人 |
| 干预（药物） | Osimertinib + Savolitinib, Savolitinib + Placebo |
| 开始日期 | 2020年9月28日 |
| 完成日期 | 2022年12月21日 |
| 结果公布日 | 2024年9月24日 |
摘要
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Objective Response Rate (ORR)
| Savolitinib Plus Osimertinib | 57.1 Percentage of participants |
|---|---|
| Savolitinib Plus Placebo | 12.5 Percentage of participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC